Strategies for Lynch syndrome identification in selected and unselected gynecological cancers
- PMID: 34519692
- DOI: 10.1097/CEJ.0000000000000711
Strategies for Lynch syndrome identification in selected and unselected gynecological cancers
Abstract
Background: Endometrial carcinoma represents a sentinel cancer for Lynch syndrome (LS) identification. It is crucial to highlight how other types of tumors can arise in the gynecological tract acting as sentinel tumors in LS patients.Up to now, no established LS patient management strategy has incorporated the presence of these additional candidate sentinel tumors to improve the prevention and management of LS tumors.
Methods: In order to investigate the involvement of the most frequent gynecological cancers in gynecological cancers, we studied different subsets of gynecological cancers using both somatic approaches, including mismatch repair (MMR) gene immunohistochemical expression, microsatellite instability, and germline analyses ofMSH2, MSH6, MLH1, PMS2 and EPCAM genes.A total of 261 patients referring to the Cancer Genetic Counselling Service of our institution were included in the study. In detail, our series was composed of 131 patients affected by uterus cancers including endometrial, isthmus and non-HPV endocervical carcinomas, 113 patients affected by ovarian cancers and 17 patients affected by synchronous endometrial/ovarian carcinomas (SEOC).In addition, we studied 115 cases of endometrial cancers identified by 2 years of universal testing (endometrial cancers/UTs) using IHC analysis of four MMR proteins.
Results and conclusions: The incidence of MMR defective gynecological cancers ranged from 7.1 to 47.1% depending on cancer site and selection. LS patients carriers of pathogenetic MMR variants were identified in 19.8% of uterus cancers, 35.3% of SEOC, 4.4% of ovarian cancers. In addition, pathogenetic MMR variants were identified in 4.3% of endometrial cancers/universal testing investigated with universal screening.In conclusion, gynecological cancers are heavily involved in LS and our study shows that MMR screening using immunohistochemical pattern and MSI analysis of endometrial and ovarian cancers as well as of rare entities such as non-HPV related endocervical cancers and synchronous endometrial and ovarian cancers are sentinels for LS.Tumor testing approach improves early identification of MMR defective gynecological cancers and this is an effective strategy to detect high-risk patients and to offer them and their relatives personalized cancer prevention.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Similar articles
-
Association of tumor morphology with mismatch-repair protein status in older endometrial cancer patients: implications for universal versus selective screening strategies for Lynch syndrome.Am J Surg Pathol. 2014 Jun;38(6):793-800. doi: 10.1097/PAS.0000000000000177. Am J Surg Pathol. 2014. PMID: 24503759
-
Comparison of screening strategies for Lynch syndrome in patients with newly diagnosed endometrial cancer: a prospective cohort study in China.Cancer Commun (Lond). 2019 Jul 15;39(1):42. doi: 10.1186/s40880-019-0388-2. Cancer Commun (Lond). 2019. PMID: 31307542 Free PMC article.
-
Lessons learnt from implementation of a Lynch syndrome screening program for patients with gynaecological malignancy.Pathology. 2017 Aug;49(5):457-464. doi: 10.1016/j.pathol.2017.05.004. Epub 2017 Jun 30. Pathology. 2017. PMID: 28669579
-
Characterization of mismatch-repair/microsatellite instability-discordant endometrial cancers.Cancer. 2024 Feb 1;130(3):385-399. doi: 10.1002/cncr.35030. Epub 2023 Sep 26. Cancer. 2024. PMID: 37751191 Free PMC article. Review.
-
Universal endometrial cancer tumor typing: How much has immunohistochemistry, microsatellite instability, and MLH1 methylation improved the diagnosis of Lynch syndrome across the population?Cancer. 2019 Sep 15;125(18):3172-3183. doi: 10.1002/cncr.32203. Epub 2019 May 31. Cancer. 2019. PMID: 31150123 Review.
Cited by
-
Lynch Syndrome and Gynecologic Tumors: Incidence, Prophylaxis, and Management of Patients with Cancer.Cancers (Basel). 2023 Feb 22;15(5):1400. doi: 10.3390/cancers15051400. Cancers (Basel). 2023. PMID: 36900193 Free PMC article. Review.
References
-
- Bartosch C, Clarke B, Bosse T. (2018). Gynaecological neoplasms in common familial syndromes (Lynch and HBOC). Pathology 50:222–237.
-
- Burn J, Sheth H, Elliott F, Reed L, Macrae F, Mecklin JP, et al.; CAPP2 Investigators. (2020). Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial. Lancet 395:1855–1863.
-
- Chiaravalli AM, Carnevali I, Sahnane N, Leoni E, Furlan D, Berselli M, et al. (2020). Universal screening to identify Lynch syndrome: two years of experience in a Northern Italian Center. Eur J Cancer Prev 29:281–288.
-
- Cini G, Carnevali I, Sahnane N, Chiaravalli AM, Dell’Elice A, Maestro R, et al. (2021). Lynch syndrome and Muir-Torre phenotype associated with a recurrent variant in the 3’UTR of the MSH6 gene. Cancer Genet 254–255:1–10.
-
- Cini G, Carnevali I, Quaia M, Chiaravalli AM, Sala P, Giacomini E, et al. (2015). Concomitant mutation and epimutation of the MLH1 gene in a Lynch syndrome family. Carcinogenesis 36:452–458.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous